scholarly journals Addressing current challenges in adult nursing: Describing a virtual consensus development project methodology

Nursing Open ◽  
2021 ◽  
Author(s):  
Bethany Taylor ◽  
Jane South ◽  
Steve Robertson ◽  
Tony Ryan ◽  
Emily Wood ◽  
...  
Keyword(s):  
Development Project ◽  
Consensus Development

Expansion of Immature/Transitional B-Lymphocytes in Patients with Active Chronic Graft-Versus-Host Disease.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1065-1065
Author(s):  
Michal Kouba ◽  
Hildegard T. Greinix ◽  
David Pohlreich ◽  
Ulrike Körmöczi ◽  
Imke Lohman ◽  
...  
Keyword(s):  
B Cell ◽  
B Lymphocytes ◽  
Graft Versus Host Disease ◽  
Immune Reconstitution ◽  
B Lymphocyte ◽  
Development Project ◽  
Consensus Development ◽  
Graft Versus Host ◽  
Cell Subpopulations ◽  
Sampling Event

Abstract Background: Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and an important cause of non-relapse mortality. The diagnosis of cGVHD depends mainly on clinical signs and histopathological confirmation. CGVHD is known to impair immune reconstitution. Recently, we observed that percentages of both non-class-switched (CD19+/IgD+/CD27+) and class-switched memory B-lymphocytes(CD19+/IgD−/CD27+) were significantly lower in patients with active cGVHD when compared to patients never experiencing cGVHD (p=0.003 and p= 0.001). The ratio of immature/memory B-lymphocytes (CD21−/CD27+) was significantly higher in patients with active cGVHD when compared to patients never experiencing cGVHD (p=0.0046). In the current study we investigated the influence of cGVHD on the pattern of immune reconstitution of B-cell subpopulations within the first years after HSCT. Methods: Ninety-nine patients (median age 42 years, range 17–62 years) were analyzed 3 months to 12 years after HSCT. The total of 212 sampling events included 141 samples obtained during active cGVHD and 71 samples from time points without cGVHD. Evidence of cGVHD in at least one organ as defined by the NIH Consensus Development Project was required to assign the sampling event into the active cGVHD group. The series included 10 patients (3 without and 7 developing cGVHD) assessed serially in 3 months’ intervals within the first years after HSCT. Peripheral blood leukocytes were analyzed by multiparameter flow cytometry after staining for CD19, staining for surface Ig and the B-lymphocyte memory marker CD27 as well as staining for CD21, which is absent on immature/transitional B-lymphocytes. The patients were scored for cGVHD activity according to the NIH Consensus Development Project criteria at every sampling event. Results: While the CD21−/CD27+ ratio as well as the percentage of immature/transitional B-lymphocytes decreased in the first years after HSCT in patients without cGVHD, these parameters remained significantly higher over the years in patients with active cGVHD (p=0.001). In logistic regression analysis a higher CD21−/CD27+ ratio and higher percentage of immature B-lymphocytes (CD21−) significantly correlated with active cGVHD. The odds ratio increased from 1.028 to 14.532 between the second and seventh year after HSCT. Until the end of the first year after HSCT serially sampled patients without cGVHD and the ones with cGVHD responding to immunosuppressive therapy presented a decrease of immature/transitional B-lymphocytes and increase of class-switched memory B cells whereas this pattern was disturbed in all serial patients with refractory cGVHD. Conclusions: Our study demonstrates that cGVHD is associated with an impairment of the reconstitution of the B-lymphocyte compartment leading to a long-lasting expansion of immature/transitional B-lymphocytes. Prospective studies with larger patient numbers analyzed serially are warranted for further assessment of the role of B-cell subpopulations in the pathogenesis of cGVHD and as potential biomarkers for cGVHD activity.

A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. TPS7072-TPS7072 ◽  
Author(s):  
David Bernard Miklos ◽  
Madan H. Jagasia ◽  
Hildegard Greinix ◽  
Bor-Sheng Ko ◽  
David A. Jacobsohn ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Response Rate ◽  
Systemic Treatment ◽  
Underlying Disease ◽  
Development Project ◽  
Phase Iii ◽  
Consensus Development ◽  
Double Blind ◽  
Host Disease ◽  
Graft Versus Host

TPS7072 Background: Chronic graft versus host disease (cGVHD) is a common complication of allogeneic stem cell transplantation, with pathophysiology involving alloreactive and dysregulated T and B cells and innate immune populations. Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of patients (pts) with CLL/SLL. Ibrutinib recently received breakthrough therapy and orphan drug designation for the treatment of pts with cGVHD who did not respond to one or more lines of systemic therapy. Ibrutinib reduces severity of cGVHD in murine models and recently was shown to achieve an NIH-defined overall response rate of 67% in pts with steroid relapsed/refractory cGVHD (Miklos Blood 2016). Methods: The primary objective of this Phase 3, multicenter, international, randomized, controlled, double-blind study is to evaluate the 24-week response rate of ibrutinib versus placebo in combination with prednisone. Pts with newly diagnosed moderate or severe cGVHD, as per NIH Consensus Development Project Criteria (2014), will be randomized in a 1:1 ratio to receive either oral ibrutinib (arm A) or placebo (arm B) in combination with oral prednisone. Ibrutinib or placebo will be given until unacceptable toxicity, relapse of underlying disease, death, or the need for a new systemic treatment for progressive cGVHD. Eligible study pts (age ≥12 yrs) must require systemic treatment with corticosteroids and have no prior systemic treatment for cGVHD. The primary endpoint is response rate (complete or partial response) at 24 weeks, as per NIH Consensus Development Project Criteria, and must occur in the absence of both new therapy for cGVHD and relapse/return of the underlying disease that was the indication for transplant. Secondary endpoints will assess for additional clinical benefit including corticosteroid dose reduction, improvement of Lee cGVHD Symptom Scale scores, withdrawal of all immunosuppressants, and overall survival. This study is currently enrolling pts. Funding source: Pharmacyclics LLC, an AbbVie Company. Clinical trial information: NCT02959944.

Sign in / Sign up

Export Citation Format

Share Document